When I originally invested in this company, for all purposes it appeared to be a truly legitimate investment. Needless to say, that was years ago. When are the people that "be" running this company going to be concerned at all with company value. Doesn't appear to have any.

Really? My brokerage only margins on $4 and higher pps.

Once $4 is solid again...we should start to see cummulation compounded as ppl will start to buy on margin.

Nice 66k share AH trade.

An intended back a##ward comment. It simply amazes me how this sort of crap manipulation is allowed and tolerated by seemly "everyone"....rather, almost expected. It's pure BS!

This guy is "f-in" comical. Such a shame his article (imho) was capable of playing such an influence in the stock's share price.

Neoprobe: Why I'm Closing My Short Position 1 comment | by: Martin Shkreli August 5, 2011 | about: NEOP Font Size: PrintEmail Recommend 0 Share this page
Share inShare0I am closing my short recommendation for Neoprobe (NEOP) at $2.00. I think the risk/reward of shorting NEOP is not so favorable as to initiate a short. I still think the stock has more downside. I have material concerns about the study design and study results of Lymphoseek.

I also think sales of Lymphoseek will be tiny. However, I cannot in good faith recommend shorting Neoprobe to you at this price. I do not think being long makes sense, either, however. If I found myself in a position where I was long Neoprobe, I would sell and move on to my two other published long ideas: Biomarin (BMRN) and Chelsea (CHTP).

Neoprobe was $5.25 when I submitted my article to Seeking Alpha. Today it is $2.00, a decline of 61%. I believe in all of my other published ideas and will inform you in this manner when I "close" them. Hopefully, this way, I will build an online "track record" for you, the general public. I am not perfect and I will make lots of mistakes. Picking stocks is a journey for information and opinions and together I think we can succeed.

Disclosure: I am short NEOP.

Additional disclosure: I may change my position at any time without notifying Seeking Alpha.

What's up with AMAG...? Saw article headline but I don't have subscription so could not read the article.

NEOP officially added to Russell 3000

http://www.russell.com/indexes/tools-resources/reconstitution/reconstitution-changes.asp

Whoah!!

thanks trishy....

What's the certainty that neop will be on the list?

Any thoughts on what time the Russell announcement will be? (a.m. or p.m. release?)

Yes...a BIG Pr!ck!

PPL on margin have maintenance calls to cover if the close is still below $4...any thoughts.

Martin is a real A##H#ole!

Thoughts...does anyone feel like we'll get a close today above $4?

Went to the link, but said page not found...what news is out???

Figured it to be manipulation...just now sure the purpose...

Sorry didn't mean to post to this board...MSFT fan though....FWIW

Question:

What do the 100 block repetative buys indicate?

Thanks in advance.
3bb

The FDA should not consider complaint issued by ANYONE who has any financial gain by such a claim...ludicrous if they do!

cool!

Shaken the trees to see what falls....solid company.

I guess it boils down to whether one is trading the stock or "investing" in the stock.

With regards to the bearish article....he did this once before that I experienced...dropped the stock, which 7-10 later...rebounded better than ever.


Traders bailed...investors still in...

GLTY
3BB

Russell 3000...has anyone heard or know if the rumor of moving to the R3000 board is legit or not?

Hi dade....yea I guess I should know better...

Have a GREAT evening!

I'm sorry...but....seriously. WOW! Isn't the knowledge on this board a bit more sophisticated than this?

FDA Minutes News....Bodes well for OXGND

SOUTH SAN FRANCISCO, Calif., March 21, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has received minutes from a Type C meeting held on March 16, 2011, between OXiGENE and the US Food and Drug Administration (FDA) to discuss next steps in the development of ZYBRESTAT as a potential treatment for anaplastic thyroid cancer (ATC).



As the company anticipated, the FDA indicated at the meeting that the data from the FACT trial are suggestive of possible clinical activity that may warrant continued development, and that to seek regulatory approval, OXiGENE should plan to conduct an additional clinical trial with a survival endpoint. The FDA also confirmed that, as the company had expected, the Special Protocol Agreement (SPA) that had been agreed upon at the start of the study is no longer in effect.



"We appreciate the candid discussions and constructive feedback we received from the FDA representatives," said Peter Langecker, Chief Executive Officer of OXiGENE. "We believe that the totality of the data, which showed that of 84 ATC patients treated with ZYBRESTAT, 20 (approximately 24%) survived one year or longer as compared to a historical rate of less than 10%, provides a compelling basis for further study."



Dr. Langecker added: "We continue to be encouraged by the outcomes in all of our clinical studies to date, including the ATC study, and are reviewing our options to further develop our VDA therapies and the additional funding that would be needed through strategic partnerships and equity financing."



The company has submitted an abstract and expects to present the final data from the FACT study, an 80-patient, randomized, controlled trial of ZYBRESTAT in combination with carboplatin and paclitaxel in patients with ATC at ASCO in June 2011.

FROM BVIG BOARD.....Yep, A Mess is how Ken described it to me and now I see on FB that a very loyal long fish sold out after finding out the float was increased yesterday by 230 million shares. Funny the longs did not post that all over the KATX board. So now we know who is selling to pay bills. Well, at least the truck payment and the Steads salaries. No sure knowing that that Rules buy at this point is a good idea as major dilution continues and a death spiral seems to be happening. That can only result in more pain as they paint themselves into a corner. I suspect just a matter of time they do another RS like before and start all over again. I guess it is hard to stop an addiction to OPM. Since Katx looks DOA for now I suspect that unless they move KATX to BVIG that the action, if any, in 2011 will be over at BVIG. Since the Steads will be free to sell shares in July I suspect we see action there next. Follow the money folks as you can trust it more than the Steads or have you not learned that yet. I just hope that the SEC catches on to the game.

You're totally wrong and off base...I am not a basher nor was that what I was trying to do. I've spoken to the company directly and that was thrown out as a strong possibility for whatever reason. I actually do the the strangest thing when buying a stock/investing in a company....I call the company and learn about them...WOW what a concept!!!

Bull....sorry for not replying sooner but with 3 babies busy....I am....LOL

Back in late Nov/early Dec...during the first pop to the .70 range I called and asked to speak to Glenn B. Left message and he called me back...we had a very nice conversation and he comes across having a very clear picture in mind of where he wants and plans on taking the company. His expertise and past successes lies in turning around troubled companies. He said that a reverse share would be a likely scenario for the company. I'm not a proponent of RS and believe that they are a huge negative for companies more times than they help.

I should have delved more in to the reasons why but I was late going in to a meeting and needed to end the call. From my DD, it appears to me, that if they do not get FDA approval that the companies liquidity is not strong enought to survive. Maybe there will be a reverse merge in to an already existing nasdaq company....who knows I don't.

Could I have misunderstood...possibly....I reitterated what I thought I heard him say though so I doubt it. I encourage those that are looking at the stock as an investment and not a day trade or flip trade to take the time and contact the company.

Take care....3bb

Yes...I agree. By chance, have either you or Bull called the company and talked to anyone directly as to the direction they would like to pursue in regards to uplisting exchanges or company direction in general? I have.....

DD I've done.

I'm betting there will be a reverse split....

And you know this HOW?

TSA Approval...Any thoughts on timeline for TSA approval?

Thanks for responses...much appreciate them!
3BB

Being a nasdaq stock there a much better chance of a R/S survival....R/S on pinks ot OTC....NEVER work. The fact that there is insider buying is a big PLUS. I guess being in medicine and having all the time of study's before result thus no immediate gratification for investors the R/S is the ONLY way the company can remain on the Nasdaq....which is the best/only place to be and remain legitimate.

IMHO....

Great Post...

My main concern is with so much dilution I expect the company to soon come to shareholders and say we need a R/S in order to up our share price and appeal to larger institutional investors. Also, I am of the belief that the PR came out conveniently when insiders filed to sell restricted shares. They get a nice pop from penny'ish to sub-penny'ish all the way to the 3 cent range....awefully convenient imo.

When do the insider restricted shares actually hit the market and sell...I thought I saw 2/15 on one of them????

Why did company choose NOT to disclose who the digital content partner is?